SCHEMBL4639358

SCHEMBL4639358

Cc1cc(OCc2ccccc2)ccc1-c1c(C)c(C(=O)O)cn1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.48
S1PR5 Q9H228 1/20 0.48
SRD5A2 P31213 1/20 0.47
MAOB P27338 1/20 0.47
ALKBH1 Q13686 1/20 0.45
LTB4R Q15722 2/20 0.45
LTB4R2 Q9NPC1 2/20 0.45
MRGPRX4 Q96LA9 1/20 0.45
MCL1 Q07820 2/20 0.44
NR4A2 P43354 2/20 0.44
SLC16A3 O15427 1/20 0.44
NR4A1 P22736 1/20 0.44
NR4A3 Q92570 1/20 0.44
PTGER1 P34995 1/20 0.44
P4HTM Q9NXG6 1/20 0.43
TOP1 P11387 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
MDH2 P40926 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4638788 0.84 MRGPRX4 (0.51) SRD5A2MAOBALKBH1MRGPRX4NR4A2
SCHEMBL2437481 0.81 NR3C2 (0.48) MAOBALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4638610 0.81 PTGER1 (0.63) MCL1PTGER1SMN1; SMN2
Benzene SCHEMBL28056879 0.78 MAOB (0.64) SRD5A2MAOBLTB4RLTB4R2MRGPRX4
SCHEMBL1022035 0.78 MAOB (0.64) SRD5A2MAOBLTB4RLTB4R2MRGPRX4
SCHEMBL2433126 0.78 LTB4R (0.55) SRD5A2MAOBLTB4RLTB4R2MCL1
SCHEMBL4638882 0.77 PTGER1 (0.53) MRGPRX4MCL1PTGER1SMN1; SMN2
SCHEMBL4887884 0.77 ESR2 (0.44) ALDH1A1MEN1KMT2A
Hydrochloric Acid SCHEMBL9440598 0.77 MAOB (0.62) SRD5A2MAOBLTB4RLTB4R2MRGPRX4
SCHEMBL22134269 0.76 S1PR1 (0.45) S1PR1S1PR5SRD5A2MAOBTOP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP claimed
US-8367667-B2 Pyrrole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2013-02-05 US claimed
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2011-12-08 US claimed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US claimed
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP claimed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP claimed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO claimed
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP disclosed
US-8367667-B2 Pyrrole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2013-02-05 US disclosed
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2011-12-08 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 S1PR1 387/4885S1PR5 400/4885SRD5A2 1490/4885
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 S1PR1 387/4885S1PR5 400/4885SRD5A2 1490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.